data_1bvg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1bvg _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.578 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.632 0 N-CA-C 110.014 -0.802 . . . . 1.08 110.014 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.531 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 11.8 tt0 -84.07 137.75 33.41 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.009 -1.108 . . . . 2.12 108.009 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.518 HG13 ' CB ' ' A' ' 9' ' ' PRO . 54.4 t -140.28 96.66 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 120.781 -1.199 . . . . 1.49 110.109 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.475 ' CG2' ' CG2' ' B' ' 96' ' ' THR . 1.2 p -114.69 -71.98 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.59 -0.893 . . . . 2.29 108.59 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.552 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 38.64 37.35 0.18 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.655 -0.653 . . . . 5.14 110.043 179.42 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.569 ' CE3' ' HB ' ' B' ' 91' ' ' THR . 6.6 m95 18.04 51.38 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.433 0.635 . . . . 1.87 111.277 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.544 ' N ' ' O ' ' A' ' 5' ' ' LEU . 7.5 mt-30 -157.83 -167.29 2.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.56 -0.713 . . . . 3.02 109.31 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.506 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 8.4 mtt180 -73.89 119.29 75.42 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 3.31 109.429 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.518 ' CB ' HG13 ' A' ' 3' ' ' VAL . 34.3 Cg_endo -77.92 77.2 4.01 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.281 1.987 . . . . 0.93 110.167 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.528 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -84.09 146.77 27.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 1.54 109.754 -179.693 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.525 ' CG2' HG21 ' A' ' 66' ' ' ILE . 2.0 m -131.2 133.18 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 1.51 109.571 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -65.65 104.43 1.03 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.087 -1.008 . . . . 1.6 108.482 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.59 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -90.75 152.73 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.207 -0.933 . . . . 1.27 110.516 -178.935 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.5 ' CA ' HD22 ' A' ' 19' ' ' LEU . 17.3 tttt -124.13 93.73 4.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.471 -0.768 . . . . 2.14 109.046 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.532 HG21 ' CG2' ' A' ' 62' ' ' ILE . 18.7 mt -117.68 150.42 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.193 -0.942 . . . . 1.44 109.688 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.438 ' O ' ' HG3' ' A' ' 18' ' ' GLN . . . 41.92 54.62 4.31 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.098 -1.201 . . . . 1.21 110.098 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 45.68 46.54 13.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.552 -1.419 . . . . 1.09 109.552 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.491 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.4 mt-30 -142.51 165.95 26.0 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.398 -1.06 . . . . 2.96 108.964 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.5 HD22 ' CA ' ' A' ' 14' ' ' LYS . 18.8 mt -138.81 129.49 26.19 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.126 -0.984 . . . . 1.72 109.848 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -150.45 166.56 29.76 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.495 -0.753 . . . . 2.84 109.092 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.528 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.0 mt-10 -79.96 134.61 36.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.133 -0.979 . . . . 2.5 109.168 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.59 ' CB ' ' CG2' ' A' ' 13' ' ' ILE . . . -115.05 127.71 55.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 1.15 109.946 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.555 ' O ' ' N ' ' A' ' 25' ' ' ASP . 25.6 tp -81.3 102.4 10.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.254 -0.904 . . . . 1.26 108.613 179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.512 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 8.3 mt -43.94 95.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.334 -0.987 . . . . 1.55 108.334 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.58 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 22.6 t0 -98.32 72.06 2.09 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.466 -0.771 . . . . 1.37 110.726 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.53 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 5.4 m -61.0 -15.02 26.98 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.047 -1.033 . . . . 1.25 108.287 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.533 ' O ' ' CD2' ' B' ' 23' ' ' LEU . . . -72.42 -42.2 49.66 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.638 -1.385 . . . . 0.52 109.638 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.533 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -70.57 160.39 32.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.199 -1.177 . . . . 1.14 109.76 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.445 ' OD2' ' CD ' ' B' ' 8' ' ' ARG . 1.7 m-20 -97.94 -10.39 24.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 1.63 109.512 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.55 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -136.94 -179.67 5.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -0.909 . . . . 1.36 109.354 179.894 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.466 ' O ' ' HA ' ' A' ' 75' ' ' VAL . 92.9 m -104.78 88.68 2.97 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.986 -1.072 . . . . 1.1 110.443 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.79 169.19 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 107.534 -1.284 . . . . 1.18 107.534 178.706 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.592 ' CD1' ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -166.95 123.23 1.17 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.881 -1.137 . . . . 1.11 110.173 -179.096 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.598 ' N ' ' CG2' ' A' ' 80' ' ' THR . 11.0 pt-20 -44.27 155.67 0.09 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.73 -0.841 . . . . 2.25 108.73 179.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.53 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.3 tt0 -44.34 141.22 1.94 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.164 -0.96 . . . . 2.03 109.612 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.52 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -149.36 -160.22 1.14 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.388 -0.82 . . . . 1.46 109.779 -179.685 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.402 ' HB2' ' NE2' ' A' ' 18' ' ' GLN . 9.4 t -101.09 90.86 4.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.364 -0.835 . . . . 1.94 110.124 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.583 HD22 ' CG ' ' A' ' 59' ' ' TYR . 3.1 tp -126.21 142.7 43.46 Favored Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 108.615 -0.883 . . . . 2.24 108.615 179.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.486 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 33.4 Cg_endo -75.11 160.28 39.98 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.417 2.078 . . . . 2.6 110.39 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -58.0 -157.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.311 -1.116 . . . . 3.01 110.311 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.503 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 77.19 47.21 0.06 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.773 -0.839 . . . . 5.63 109.384 -179.323 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.624 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 35.0 p-90 -138.25 -170.43 2.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.644 -0.66 . . . . 1.71 109.892 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -133.38 138.65 31.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 N-CA-C 108.58 -0.896 . . . . 3.71 108.58 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.84 138.45 16.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 122.065 1.843 . . . . 1.89 110.299 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.53 ' HD2' ' CG2' ' A' ' 56' ' ' VAL . 0.8 OUTLIER -156.49 -174.14 4.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.265 -0.897 . . . . 2.94 109.624 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.501 ' CG ' ' CG ' ' A' ' 55' ' ' LYS . 6.3 mtp -150.56 131.56 14.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.321 -0.862 . . . . 1.79 109.212 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.592 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 8.7 pt -99.55 145.68 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 1.35 109.14 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.579 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -119.04 104.01 1.04 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.712 -1.755 . . . . 0.72 108.712 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.45 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -126.63 -126.16 2.91 Favored Glycine 0 N--CA 1.486 1.981 0 C-N-CA 119.456 -1.354 . . . . 0.55 110.829 -178.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.6 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 24.8 mt -83.7 120.2 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.764 -0.845 . . . . 1.19 112.237 -177.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.16 -54.46 0.61 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.092 -1.203 . . . . 0.65 110.092 178.499 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.07 -161.06 25.99 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.743 -1.343 . . . . 0.62 109.743 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -108.85 124.94 51.42 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 2.02 109.576 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.592 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 9.6 pt -99.43 161.11 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.166 -0.959 . . . . 1.36 108.976 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 39.6 mttt -100.11 132.32 45.55 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.135 -0.978 . . . . 3.2 109.423 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.53 ' CG2' ' HD2' ' A' ' 45' ' ' LYS . 29.1 m -138.7 173.67 11.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.963 -1.086 . . . . 1.31 109.924 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.584 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 5.8 mtt85 -117.43 109.55 16.92 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 108.871 -0.788 . . . . 3.16 108.871 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.406 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 11.9 tt0 -63.66 95.35 0.1 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.168 -0.957 . . . . 2.35 109.529 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.624 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 6.2 m-85 -91.28 93.46 9.08 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 108.857 -0.794 . . . . 1.51 108.857 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.544 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 16.3 m-20 -79.85 130.85 35.65 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 1.77 109.98 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.544 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.4 OUTLIER 84.35 60.2 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.722 0 CA-C-O 121.3 0.571 . . . . 2.4 110.152 179.543 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.54 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 9.1 mm -116.74 114.76 46.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.478 -0.934 . . . . 1.99 108.478 179.03 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.543 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.7 tm? -66.23 86.08 0.1 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 2.02 110.415 -179.03 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.542 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 2.8 tt -92.8 120.8 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 N-CA-C 108.3 -1.0 . . . . 1.17 108.3 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.487 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.5 tt0 -92.29 107.05 18.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.984 . . . . 2.26 109.743 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.529 HD12 ' CD1' ' A' ' 64' ' ' ILE . 1.6 mp -110.21 124.64 67.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.339 -0.851 . . . . 1.44 108.989 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.474 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 65.22 50.37 1.8 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.487 -0.758 . . . . 1.69 109.431 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 48.73 32.52 11.18 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.537 -1.425 . . . . 1.53 109.537 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.474 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 72.6 m-70 -129.95 128.01 41.24 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -1.167 . . . . 2.92 109.55 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.542 ' CG ' HD23 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -63.12 139.13 58.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.295 -0.878 . . . . 4.25 109.035 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.542 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -158.99 100.03 1.55 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.165 -0.96 . . . . 1.32 110.212 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.525 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -79.83 152.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.89 -1.131 . . . . 1.5 108.352 178.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -177.61 -177.55 46.52 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.029 -1.558 . . . . 0.77 110.998 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.457 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 3.8 m -91.02 106.39 18.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -1.041 . . . . 1.38 110.01 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.592 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.3 t -100.71 115.45 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.489 -0.757 . . . . 1.15 109.75 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.55 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 3.7 mp -82.93 110.57 18.03 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.275 -0.891 . . . . 1.45 109.445 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.531 HG22 ' CD2' ' A' ' 59' ' ' TYR . 13.7 t -90.31 115.11 29.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.109 -0.995 . . . . 1.43 109.828 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -149.46 -168.44 14.93 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.042 -1.623 . . . . 0.71 109.042 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -80.64 42.63 1.37 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.615 2.21 . . . . 0.83 110.759 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.598 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 7.1 t -86.79 138.32 33.29 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 1.27 108.451 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.466 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 36.5 Cg_endo -79.27 16.55 1.36 Allowed 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.557 2.171 . . . . 0.66 111.229 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.1 t -160.79 156.89 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.883 -1.136 . . . . 1.27 110.014 -179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.541 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 74.4 m-20 -91.29 92.94 8.84 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 106.735 -1.58 . . . . 1.44 106.735 177.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.58 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 5.7 mm -80.02 129.25 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.414 -0.804 . . . . 1.26 112.249 -176.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.536 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 1.1 mp -110.02 106.87 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.138 -1.43 . . . . 1.22 107.138 177.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -93.25 -162.19 36.35 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.999 -1.096 . . . . 0.51 110.575 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.485 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 25.6 mmm-85 -63.7 -38.42 91.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.635 -0.921 . . . . 4.97 109.917 -179.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.534 ' ND2' HD21 ' A' ' 89' ' ' LEU . 10.6 p-10 -43.59 -28.17 0.36 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 1.02 109.543 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.538 ' CD2' ' HA3' ' A' ' 73' ' ' GLY . 1.2 mm? -108.66 -29.72 8.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.853 . . . . 1.25 109.953 -179.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.53 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 56.3 mt -67.55 -9.58 43.94 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.098 -1.001 . . . . 1.74 108.441 179.17 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.567 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 45.9 p -92.7 -20.46 20.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.297 -0.877 . . . . 1.55 108.74 179.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.2 mm-40 -86.82 -40.94 14.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 2.36 108.971 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.557 HD13 ' CG ' ' B' ' 99' ' ' PHE . 1.3 pt -83.1 -5.62 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 N-CA-C 108.643 -0.873 . . . . 1.28 108.643 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.66 31.32 65.3 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.815 -0.914 . . . . 0.75 110.815 178.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.555 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -61.61 148.07 43.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.897 -1.355 . . . . 1.11 109.565 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.1 p -144.33 131.59 20.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.298 -0.876 . . . . 1.47 108.785 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.6 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 4.5 mp -92.02 90.22 7.3 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.231 -0.918 . . . . 1.33 109.696 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.577 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.2 m120 -97.72 125.61 42.62 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.119 -0.988 . . . . 0.86 108.991 179.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.582 ' CD2' HD13 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 117.955 -1.021 . . . . 1.36 109.429 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.532 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.496 1.65 0 N-CA-C 110.296 -0.694 . . . . 0.97 110.296 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.577 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.5 tt0 -84.53 138.96 32.46 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.864 -1.162 . . . . 2.02 107.864 178.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.478 HG11 ' HB3' ' B' ' 9' ' ' PRO . 25.4 t -138.72 106.44 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 120.822 -1.174 . . . . 1.58 110.331 -178.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.439 ' O ' ' C ' ' B' ' 5' ' ' LEU . 3.9 p -119.79 -73.26 0.65 Allowed 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.38 -0.971 . . . . 2.12 108.38 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 38.93 37.91 0.24 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 4.76 110.12 179.211 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.567 ' CD2' ' HB ' ' A' ' 91' ' ' THR . 7.6 m0 17.92 50.94 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.363 0.601 . . . . 1.76 111.557 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.7 mt-30 -157.86 -167.33 2.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.362 -0.836 . . . . 3.59 109.496 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.445 ' CD ' ' OD2' ' A' ' 29' ' ' ASP . 1.5 mtt180 -73.3 120.95 83.75 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 3.24 109.514 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.485 ' HB2' ' CD1' ' B' ' 24' ' ' LEU . 34.8 Cg_endo -77.85 72.77 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.366 2.044 . . . . 0.88 110.218 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.524 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -80.91 154.41 27.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 1.5 109.73 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.468 HG22 HG21 ' B' ' 13' ' ' ILE . 2.5 m -143.79 131.6 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.372 -0.83 . . . . 1.44 109.428 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.2 m -69.08 108.0 3.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.11 -0.993 . . . . 1.65 108.526 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.569 HG22 ' CB ' ' B' ' 22' ' ' ALA . 5.1 pt -96.06 151.95 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.104 -0.997 . . . . 1.36 110.61 -178.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.513 ' CA ' HD22 ' B' ' 19' ' ' LEU . 1.5 tttt -117.22 92.75 3.94 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.52 -0.918 . . . . 2.36 108.52 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.601 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 13.6 mt -109.88 121.25 62.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.128 -0.982 . . . . 1.48 110.477 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 58.06 53.36 46.17 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.985 -1.246 . . . . 1.67 109.985 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.24 15.94 17.62 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.751 -1.339 . . . . 1.51 109.751 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 21.4 mm-40 -108.52 170.79 7.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -1.144 . . . . 2.64 108.982 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.525 ' CD2' ' O ' ' B' ' 13' ' ' ILE . 14.5 mt -151.71 128.19 10.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.11 -0.994 . . . . 1.89 109.924 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.498 ' CB ' ' ND2' ' B' ' 83' ' ' ASN . 19.6 mttm -150.92 167.79 26.5 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.527 -0.733 . . . . 3.21 109.209 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.524 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 3.8 mt-10 -79.62 129.36 34.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.1 -1.0 . . . . 2.82 108.84 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.569 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -109.89 121.78 46.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.226 -0.921 . . . . 1.17 109.938 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' B' ' 25' ' ' ASP . 25.3 tp -79.77 99.02 7.27 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.64 -0.874 . . . . 1.35 108.64 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.485 ' CD1' ' HB2' ' B' ' 9' ' ' PRO . 10.4 mt -44.87 95.71 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.135 -1.061 . . . . 1.49 108.135 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.549 ' N ' ' O ' ' B' ' 23' ' ' LEU . 22.5 t0 -106.37 82.82 1.79 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.413 -0.804 . . . . 1.25 110.677 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.525 ' HA ' ' CD1' ' B' ' 90' ' ' LEU . 0.7 OUTLIER -64.35 -12.48 42.82 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.122 -1.066 . . . . 1.25 108.122 178.251 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.471 ' O ' ' CD2' ' A' ' 23' ' ' LEU . . . -68.07 -44.95 75.24 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.614 -1.394 . . . . 0.49 109.614 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.554 ' CB ' ' C75' ' B' ' 100' ' ' DMP . . . -68.49 163.93 22.31 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.267 -1.137 . . . . 1.11 109.648 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.506 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 2.0 m-20 -99.75 -13.9 19.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -0.856 . . . . 1.55 109.592 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.539 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -135.4 -175.66 4.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 1.39 109.206 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.477 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 96.1 m -106.15 91.33 3.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.953 -1.092 . . . . 1.05 110.229 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.48 168.03 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.694 -1.225 . . . . 1.29 107.694 178.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.572 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -166.26 127.0 1.73 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.954 -1.092 . . . . 1.19 110.153 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' B' ' 80' ' ' THR . 83.8 tt0 -42.39 156.73 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.511 -0.743 . . . . 2.16 109.039 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.535 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 0.6 OUTLIER -47.1 143.38 3.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.14 -0.975 . . . . 2.24 109.699 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.528 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -167.31 -174.91 2.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.386 -0.821 . . . . 1.62 109.384 179.956 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.515 ' N ' ' SD ' ' B' ' 36' ' ' MET . 7.1 t -96.84 102.47 14.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 1.8 110.334 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.582 HD11 ' CG ' ' B' ' 59' ' ' TYR . 0.0 OUTLIER -97.14 172.45 4.97 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 108.231 -1.026 . . . . 2.4 108.231 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.53 ' HD2' ' CD1' ' B' ' 38' ' ' LEU . 36.2 Cg_endo -80.13 51.79 4.05 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.715 2.277 . . . . 2.41 111.538 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.15 -160.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.318 -1.113 . . . . 2.48 110.318 179.348 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 54.65 81.54 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.441 -1.035 . . . . 5.85 109.294 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.692 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 62.3 p-90 -159.16 -175.78 5.45 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.479 -0.763 . . . . 1.77 109.952 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -140.89 146.56 44.41 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.724 -0.843 . . . . 3.27 108.724 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.24 139.86 19.17 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.36 2.04 . . . . 1.89 110.556 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.496 ' HD2' ' CG2' ' B' ' 56' ' ' VAL . 4.5 ptpt -159.51 -173.56 4.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 2.87 109.424 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.519 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 52.4 mtp -150.8 130.65 13.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 1.63 109.479 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.588 ' CG1' ' CG1' ' B' ' 54' ' ' ILE . 10.4 pt -98.03 147.36 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.091 -1.006 . . . . 1.34 109.027 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.581 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.1 106.01 1.22 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.631 -1.788 . . . . 0.74 108.631 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.432 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -129.18 -125.04 2.7 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.391 -1.385 . . . . 0.51 110.892 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.612 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 18.2 mt -84.7 120.96 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.732 -0.863 . . . . 1.13 112.281 -177.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.459 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.91 -53.95 0.69 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.081 -1.207 . . . . 0.69 110.081 178.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.57 -160.71 25.67 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.678 -1.369 . . . . 0.71 109.678 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.581 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 4.5 m-85 -108.56 125.04 51.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.365 -1.079 . . . . 2.76 109.48 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.588 ' CG1' ' CG1' ' B' ' 47' ' ' ILE . 7.5 pt -99.05 161.71 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.129 -0.982 . . . . 1.37 108.925 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.548 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.5 mttm -101.74 129.11 47.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.987 -1.071 . . . . 3.45 109.449 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.518 ' CG2' ' HB3' ' B' ' 76' ' ' LEU . 35.9 m -134.22 171.77 17.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.06 -1.025 . . . . 1.35 109.702 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.57 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.6 mtt180 -117.02 105.48 12.35 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.426 -0.796 . . . . 3.05 108.92 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.444 ' CG ' HG23 ' B' ' 74' ' ' THR . 6.0 tt0 -58.02 93.8 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.273 -0.892 . . . . 2.35 109.801 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.692 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 15.5 m-85 -89.28 91.99 8.98 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.176 -1.046 . . . . 1.38 108.176 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.553 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.5 m-20 -79.25 131.98 36.34 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.198 -0.939 . . . . 1.75 110.395 -178.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.553 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 81.82 62.38 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.53 0.681 . . . . 2.35 109.96 179.672 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.601 ' CG2' ' CG2' ' B' ' 15' ' ' ILE . 50.8 mm -118.42 115.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 108.612 -0.885 . . . . 1.9 108.612 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.549 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 3.4 tm? -65.21 85.29 0.06 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -0.807 . . . . 1.93 110.544 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.54 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 2.8 tt -93.06 115.12 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 107.917 -1.142 . . . . 1.22 107.917 178.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 72.2 tt0 -89.74 112.01 23.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.033 -1.042 . . . . 2.26 110.069 -178.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.54 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.1 mp -110.58 126.73 67.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.35 -0.844 . . . . 1.35 108.869 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.505 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 1.1 m 64.84 47.82 2.58 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.528 -0.732 . . . . 1.51 109.417 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.71 23.56 29.66 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.481 -1.448 . . . . 1.93 109.481 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.505 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 89.2 m-70 -122.62 128.21 50.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.253 -1.145 . . . . 2.42 109.396 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.524 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -66.18 142.81 57.6 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 4.01 109.35 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -159.17 102.95 1.62 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 1.45 109.595 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.528 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 1.0 OUTLIER -79.2 152.18 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.89 -1.132 . . . . 1.58 108.498 179.458 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.536 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -177.03 -176.54 45.24 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 119.177 -1.487 . . . . 0.79 110.673 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.444 HG23 ' CG ' ' B' ' 58' ' ' GLN . 1.5 m -91.49 105.91 18.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.531 -0.982 . . . . 1.36 110.127 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.572 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.4 t -99.51 110.28 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.547 -0.721 . . . . 1.13 109.815 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.539 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 3.9 mp -80.13 109.88 15.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.241 -0.912 . . . . 1.43 109.342 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.535 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 3.6 t -91.14 114.08 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.041 -1.037 . . . . 1.44 109.979 -179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -148.81 -166.72 13.21 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 108.93 -1.668 . . . . 0.8 108.93 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.548 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.19 41.83 1.2 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.581 2.187 . . . . 0.87 110.894 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' B' ' 34' ' ' GLU . 6.0 t -85.6 137.92 36.06 Favored Pre-proline 0 C--N 1.302 -1.479 0 O-C-N 121.159 -0.963 . . . . 1.24 108.415 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.461 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 36.8 Cg_endo -79.94 16.55 1.46 Allowed 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.503 2.135 . . . . 0.66 110.809 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.473 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.7 t -160.55 161.91 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 120.96 -1.087 . . . . 1.3 110.012 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.543 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 74.0 m-20 -99.8 93.71 5.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 106.651 -1.611 . . . . 1.34 106.651 177.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.538 HG22 ' CB ' ' B' ' 25' ' ' ASP . 5.3 mm -79.83 128.21 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.586 -0.696 . . . . 1.66 112.28 -176.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.524 ' CD1' ' HB2' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -106.74 94.86 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 107.136 -1.431 . . . . 1.29 107.136 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.451 ' O ' ' HG ' ' B' ' 90' ' ' LEU . . . -83.51 -161.58 31.81 Favored Glycine 0 N--CA 1.492 2.425 0 O-C-N 121.185 -0.947 . . . . 0.63 111.249 -178.002 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.499 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 31.3 mmm180 -63.88 -40.17 95.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.684 -0.892 . . . . 4.98 110.229 -179.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.53 ' ND2' HD21 ' B' ' 89' ' ' LEU . 10.7 p-10 -43.51 -30.56 0.59 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -0.938 . . . . 0.71 109.447 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.536 ' CD2' ' HA3' ' B' ' 73' ' ' GLY . 1.2 mm? -105.85 -25.07 12.31 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.296 -0.878 . . . . 1.29 109.879 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.525 ' CD1' ' HA ' ' B' ' 26' ' ' THR . 88.7 mt -74.07 -1.86 21.91 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.063 -1.023 . . . . 2.06 108.57 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.569 ' HB ' ' CE3' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -100.06 -19.91 16.29 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.357 -0.979 . . . . 1.57 108.357 179.049 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -86.97 -40.57 14.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.421 -0.799 . . . . 2.77 109.269 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.582 HD13 ' CD2' ' A' ' 99' ' ' PHE . 1.3 pt -84.35 -0.55 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.18 -0.95 . . . . 1.36 109.109 179.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 66.16 44.67 90.62 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.667 -0.973 . . . . 0.86 110.667 179.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.518 ' CB ' HD21 ' B' ' 90' ' ' LEU . . . -75.32 149.8 38.63 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.041 -1.27 . . . . 1.17 109.965 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.475 ' CG2' ' CG2' ' A' ' 4' ' ' THR . 11.7 p -142.48 128.78 19.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.646 -0.872 . . . . 1.4 108.646 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.6 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 1.7 mp -90.36 95.18 10.06 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.377 -0.827 . . . . 1.23 109.382 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.531 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 1.4 m120 -106.51 128.94 54.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.164 -0.96 . . . . 0.83 109.856 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.578 ' CE2' ' HG2' ' A' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.011 -0.995 . . . . 1.53 109.282 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.612 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.577 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.632 0 N-CA-C 110.014 -0.802 . . . . 0.98999999999999999 110.014 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -84.07 137.75 33.41 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.009 -1.108 . . . . 1.72 108.009 178.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.715 HG12 ' HB3' ' A' ' 9' ' ' PRO . 54.4 t -140.28 96.66 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 120.781 -1.199 . . . . 0.97999999999999998 110.109 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.772 ' CG2' HG22 ' B' ' 96' ' ' THR . 1.2 p -114.69 -71.98 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.59 -0.893 . . . . 2.29 108.59 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.552 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 38.64 37.35 0.18 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.655 -0.653 . . . . 4.7199999999999998 110.043 179.42 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.635 ' CG ' HG22 ' B' ' 91' ' ' THR . 6.6 m95 18.04 51.38 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.433 0.635 . . . . 1.6200000000000001 111.277 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.544 ' N ' ' O ' ' A' ' 5' ' ' LEU . 7.5 mt-30 -157.83 -167.29 2.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.56 -0.713 . . . . 2.8599999999999999 109.31 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.506 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 8.4 mtt180 -73.89 119.29 75.42 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 2.8599999999999999 109.429 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.996 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.3 Cg_endo -77.92 77.2 4.01 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.281 1.987 . . . . 0.80000000000000004 110.167 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.735 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -84.09 146.77 27.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.98999999999999999 109.754 -179.693 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.882 ' CG2' HG23 ' A' ' 66' ' ' ILE . 2.0 m -131.2 133.18 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.84999999999999998 109.571 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.533 HG22 HD22 ' A' ' 19' ' ' LEU . 3.9 m -65.65 104.43 1.03 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.087 -1.008 . . . . 1.1000000000000001 108.482 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.867 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -90.75 152.73 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.207 -0.933 . . . . 0.68000000000000005 110.516 -178.935 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.595 ' HE3' HD11 ' A' ' 19' ' ' LEU . 17.3 tttt -124.13 93.73 4.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.471 -0.768 . . . . 1.5800000000000001 109.046 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.884 HD13 HG11 ' A' ' 75' ' ' VAL . 18.7 mt -117.68 150.42 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.193 -0.942 . . . . 0.81000000000000005 109.688 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.462 ' O ' ' HG3' ' A' ' 18' ' ' GLN . . . 41.92 54.62 4.31 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.098 -1.201 . . . . 1.21 110.098 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 45.68 46.54 13.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.552 -1.419 . . . . 1.0900000000000001 109.552 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.502 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.4 mt-30 -142.51 165.95 26.0 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.398 -1.06 . . . . 2.3199999999999998 108.964 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.867 HD23 ' O ' ' A' ' 13' ' ' ILE . 18.8 mt -138.81 129.49 26.19 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.126 -0.984 . . . . 1.1799999999999999 109.848 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -150.45 166.56 29.76 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.495 -0.753 . . . . 2.3399999999999999 109.092 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.735 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.0 mt-10 -79.96 134.61 36.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.133 -0.979 . . . . 2.5 109.168 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.736 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -115.05 127.71 55.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.56999999999999995 109.946 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.97 HD21 ' O ' ' B' ' 27' ' ' GLY . 25.6 tp -81.3 102.4 10.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.254 -0.904 . . . . 0.59999999999999998 108.613 179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.996 HD12 ' HB2' ' A' ' 9' ' ' PRO . 8.3 mt -43.94 95.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.334 -0.987 . . . . 0.88 108.334 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.588 ' HB2' HG23 ' A' ' 84' ' ' ILE . 22.6 t0 -98.32 72.06 2.09 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.466 -0.771 . . . . 1.3700000000000001 110.726 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.637 HG21 HD13 ' A' ' 97' ' ' LEU . 5.4 m -61.0 -15.02 26.98 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.047 -1.033 . . . . 0.60999999999999999 108.287 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 1.028 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -72.42 -42.2 49.66 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.638 -1.385 . . . . 0.52000000000000002 109.638 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.561 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -70.57 160.39 32.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.199 -1.177 . . . . 0.48999999999999999 109.76 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.445 ' OD2' ' CD ' ' B' ' 8' ' ' ARG . 1.7 m-20 -97.94 -10.39 24.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 1.6299999999999999 109.512 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.814 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -136.94 -179.67 5.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -0.909 . . . . 1.3600000000000001 109.354 179.894 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.768 HG23 HD12 ' A' ' 85' ' ' ILE . 92.9 m -104.78 88.68 2.97 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.986 -1.072 . . . . 0.59999999999999998 110.443 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.008 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.79 169.19 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 107.534 -1.284 . . . . 0.77000000000000002 107.534 178.706 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.118 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -166.95 123.23 1.17 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.881 -1.137 . . . . 0.54000000000000004 110.173 -179.096 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.598 ' N ' ' CG2' ' A' ' 80' ' ' THR . 11.0 pt-20 -44.27 155.67 0.09 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.73 -0.841 . . . . 2.25 108.73 179.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.577 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.3 tt0 -44.34 141.22 1.94 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.164 -0.96 . . . . 2.0299999999999998 109.612 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.583 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.3 OUTLIER -149.36 -160.22 1.14 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.388 -0.82 . . . . 1.46 109.779 -179.685 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.43 ' HB2' ' NE2' ' A' ' 18' ' ' GLN . 9.4 t -101.09 90.86 4.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.364 -0.835 . . . . 1.5700000000000001 110.124 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 1.028 HD23 ' CD2' ' A' ' 59' ' ' TYR . 3.1 tp -126.21 142.7 43.46 Favored Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 108.615 -0.883 . . . . 1.6699999999999999 108.615 179.437 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.512 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 33.4 Cg_endo -75.11 160.28 39.98 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.417 2.078 . . . . 2.4399999999999999 110.39 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.517 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -58.0 -157.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.311 -1.116 . . . . 2.4300000000000002 110.311 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.517 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 77.19 47.21 0.06 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.773 -0.839 . . . . 4.8600000000000003 109.384 -179.323 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.635 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 35.0 p-90 -138.25 -170.43 2.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.644 -0.66 . . . . 1.55 109.892 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -133.38 138.65 31.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 N-CA-C 108.58 -0.896 . . . . 3.29 108.58 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.84 138.45 16.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 122.065 1.843 . . . . 1.73 110.299 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.563 ' HD2' HD23 ' A' ' 76' ' ' LEU . 0.8 OUTLIER -156.49 -174.14 4.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.265 -0.897 . . . . 2.4399999999999999 109.624 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.501 ' CG ' ' CG ' ' A' ' 55' ' ' LYS . 6.3 mtp -150.56 131.56 14.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.321 -0.862 . . . . 1.4299999999999999 109.212 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.848 ' CD1' HG21 ' B' ' 50' ' ' ILE . 8.7 pt -99.55 145.68 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.77000000000000002 109.14 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.608 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -119.04 104.01 1.04 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.712 -1.755 . . . . 0.70999999999999996 108.712 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.492 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -126.63 -126.16 2.91 Favored Glycine 0 N--CA 1.486 1.981 0 C-N-CA 119.456 -1.354 . . . . 0.52000000000000002 110.829 -178.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.855 HG21 ' CD1' ' B' ' 47' ' ' ILE . 24.8 mt -83.7 120.2 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.764 -0.845 . . . . 0.56999999999999995 112.237 -177.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.16 -54.46 0.61 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.092 -1.203 . . . . 0.65000000000000002 110.092 178.499 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.07 -161.06 25.99 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.743 -1.343 . . . . 0.55000000000000004 109.743 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.608 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -108.85 124.94 51.42 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 1.55 109.576 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.592 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 9.6 pt -99.43 161.11 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.166 -0.959 . . . . 0.79000000000000004 108.976 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 39.6 mttt -100.11 132.32 45.55 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.135 -0.978 . . . . 2.8100000000000001 109.423 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.706 HG12 ' HA3' ' A' ' 78' ' ' GLY . 29.1 m -138.7 173.67 11.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.963 -1.086 . . . . 1.01 109.924 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.584 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 5.8 mtt85 -117.43 109.55 16.92 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 108.871 -0.788 . . . . 2.6899999999999999 108.871 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.406 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 11.9 tt0 -63.66 95.35 0.1 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.168 -0.957 . . . . 2.0600000000000001 109.529 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 1.028 ' CD2' HD23 ' A' ' 38' ' ' LEU . 6.2 m-85 -91.28 93.46 9.08 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 108.857 -0.794 . . . . 1.1799999999999999 108.857 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.544 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 16.3 m-20 -79.85 130.85 35.65 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 1.77 109.98 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.544 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.4 OUTLIER 84.35 60.2 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.722 0 CA-C-O 121.3 0.571 . . . . 2.1899999999999999 110.152 179.543 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.756 ' C ' HD13 ' A' ' 72' ' ' ILE . 9.1 mm -116.74 114.76 46.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.478 -0.934 . . . . 1.3799999999999999 108.478 179.03 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.852 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.7 tm? -66.23 86.08 0.1 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 1.47 110.415 -179.03 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.93 ' CD1' HD11 ' A' ' 66' ' ' ILE . 2.8 tt -92.8 120.8 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 N-CA-C 108.3 -1.0 . . . . 0.60999999999999999 108.3 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.5 tt0 -92.29 107.05 18.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.984 . . . . 2.2599999999999998 109.743 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.93 HD11 ' CD1' ' A' ' 64' ' ' ILE . 1.6 mp -110.21 124.64 67.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.339 -0.851 . . . . 1.0 108.989 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 65.22 50.37 1.8 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.487 -0.758 . . . . 1.5700000000000001 109.431 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 48.73 32.52 11.18 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.537 -1.425 . . . . 1.3999999999999999 109.537 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 29.6 m80 -129.95 128.01 41.24 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -1.167 . . . . 2.3500000000000001 109.55 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.586 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -63.12 139.13 58.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.295 -0.878 . . . . 3.7799999999999998 109.035 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.676 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -158.99 100.03 1.55 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.165 -0.96 . . . . 0.84999999999999998 110.212 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.782 HD13 ' N ' ' A' ' 63' ' ' LEU . 1.0 OUTLIER -79.83 152.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.89 -1.131 . . . . 0.93999999999999995 108.352 178.883 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.771 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -177.61 -177.55 46.52 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.029 -1.558 . . . . 0.68999999999999995 110.998 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.468 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 3.8 m -91.02 106.39 18.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -1.041 . . . . 0.91000000000000003 110.01 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.118 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.3 t -100.71 115.45 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.489 -0.757 . . . . 0.80000000000000004 109.75 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.814 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.7 mp -82.93 110.57 18.03 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.275 -0.891 . . . . 0.75 109.445 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.613 HG23 ' HD2' ' A' ' 59' ' ' TYR . 13.7 t -90.31 115.11 29.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.109 -0.995 . . . . 0.81999999999999995 109.828 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.706 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.46 -168.44 14.93 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.042 -1.623 . . . . 0.64000000000000001 109.042 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -80.64 42.63 1.37 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.615 2.21 . . . . 0.77000000000000002 110.759 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.648 HG21 HG13 ' A' ' 32' ' ' VAL . 7.1 t -86.79 138.32 33.29 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.59999999999999998 108.451 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.644 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.5 Cg_endo -79.27 16.55 1.36 Allowed 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.557 2.171 . . . . 0.60999999999999999 111.229 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.644 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.1 t -160.79 156.89 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.883 -1.136 . . . . 0.57999999999999996 110.014 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 74.4 m-20 -91.29 92.94 8.84 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 106.735 -1.58 . . . . 1.4399999999999999 106.735 177.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.657 ' CG1' HG12 ' A' ' 32' ' ' VAL . 5.7 mm -80.02 129.25 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.414 -0.804 . . . . 0.69999999999999996 112.249 -176.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.768 HD12 HG23 ' A' ' 31' ' ' THR . 1.1 mp -110.02 106.87 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.138 -1.43 . . . . 0.56999999999999995 107.138 177.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.475 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -93.25 -162.19 36.35 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.999 -1.096 . . . . 0.51000000000000001 110.575 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.502 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 25.6 mmm-85 -63.7 -38.42 91.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.635 -0.921 . . . . 4.1299999999999999 109.917 -179.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.939 ' ND2' HD23 ' A' ' 89' ' ' LEU . 10.6 p-10 -43.59 -28.17 0.36 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 1.02 109.543 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.939 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.2 mm? -108.66 -29.72 8.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.853 . . . . 0.60999999999999999 109.953 -179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.655 HD23 HD11 ' A' ' 93' ' ' ILE . 56.3 mt -67.55 -9.58 43.94 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.098 -1.001 . . . . 1.1499999999999999 108.441 179.17 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.576 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 45.9 p -92.7 -20.46 20.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.297 -0.877 . . . . 1.0 108.74 179.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.2 mm-40 -86.82 -40.94 14.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 2.0299999999999998 108.971 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.706 HD12 ' CG ' ' B' ' 99' ' ' PHE . 1.3 pt -83.1 -5.62 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 N-CA-C 108.643 -0.873 . . . . 0.73999999999999999 108.643 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.66 31.32 65.3 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.815 -0.914 . . . . 0.68999999999999995 110.815 178.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.559 ' N ' ' HB3' ' B' ' 99' ' ' PHE . . . -61.61 148.07 43.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.897 -1.355 . . . . 0.68000000000000005 109.565 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.621 HG22 ' CG2' ' B' ' 4' ' ' THR . 7.1 p -144.33 131.59 20.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.298 -0.876 . . . . 0.82999999999999996 108.785 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.955 HD11 HD11 ' B' ' 97' ' ' LEU . 4.5 mp -92.02 90.22 7.3 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.231 -0.918 . . . . 0.66000000000000003 109.696 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.512 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.9 m-20 -97.72 125.61 42.62 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.119 -0.988 . . . . 0.85999999999999999 108.991 179.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.799 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 117.955 -1.021 . . . . 1.3200000000000001 109.429 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.532 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.496 1.65 0 N-CA-C 110.296 -0.694 . . . . 0.88 110.296 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.461 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 2.5 tt0 -84.53 138.96 32.46 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.864 -1.162 . . . . 1.5800000000000001 107.864 178.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.605 HG12 ' HB3' ' B' ' 9' ' ' PRO . 25.4 t -138.72 106.44 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 120.822 -1.174 . . . . 1.05 110.331 -178.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.621 ' CG2' HG22 ' A' ' 96' ' ' THR . 3.9 p -119.79 -73.26 0.65 Allowed 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.38 -0.971 . . . . 2.0099999999999998 108.38 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 38.93 37.91 0.24 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 4.4400000000000004 110.12 179.211 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.576 ' CD2' ' HB ' ' A' ' 91' ' ' THR . 7.6 m0 17.92 50.94 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.363 0.601 . . . . 1.6100000000000001 111.557 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.7 mt-30 -157.86 -167.33 2.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.362 -0.836 . . . . 3.0600000000000001 109.496 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.445 ' CD ' ' OD2' ' A' ' 29' ' ' ASP . 1.5 mtt180 -73.3 120.95 83.75 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 2.7599999999999998 109.514 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.709 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.8 Cg_endo -77.85 72.77 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.366 2.044 . . . . 0.78000000000000003 110.218 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.608 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -80.91 154.41 27.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.92000000000000004 109.73 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.543 HG22 ' HB3' ' B' ' 22' ' ' ALA . 2.5 m -143.79 131.6 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.372 -0.83 . . . . 0.81999999999999995 109.428 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.451 HG22 HD22 ' B' ' 19' ' ' LEU . 1.2 m -69.08 108.0 3.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.11 -0.993 . . . . 1.1699999999999999 108.526 179.279 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 1.079 HG22 HG13 ' B' ' 66' ' ' ILE . 5.1 pt -96.06 151.95 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.104 -0.997 . . . . 0.77000000000000002 110.61 -178.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.54 ' HE2' HD11 ' B' ' 19' ' ' LEU . 1.5 tttt -117.22 92.75 3.94 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.52 -0.918 . . . . 1.8300000000000001 108.52 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.911 HG23 ' CG2' ' B' ' 62' ' ' ILE . 13.6 mt -109.88 121.25 62.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.128 -0.982 . . . . 0.87 110.477 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 58.06 53.36 46.17 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.985 -1.246 . . . . 1.6699999999999999 109.985 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.24 15.94 17.62 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.751 -1.339 . . . . 1.3100000000000001 109.751 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 21.4 mm-40 -108.52 170.79 7.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -1.144 . . . . 2.3799999999999999 108.982 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 1.048 HD23 ' O ' ' B' ' 13' ' ' ILE . 14.5 mt -151.71 128.19 10.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.11 -0.994 . . . . 1.3200000000000001 109.924 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 19.6 mttm -150.92 167.79 26.5 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.527 -0.733 . . . . 2.7000000000000002 109.209 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.608 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.8 mt-10 -79.62 129.36 34.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.1 -1.0 . . . . 2.8199999999999998 108.84 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.905 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -109.89 121.78 46.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.226 -0.921 . . . . 0.71999999999999997 109.938 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 1.028 HD21 ' O ' ' A' ' 27' ' ' GLY . 25.3 tp -79.77 99.02 7.27 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.64 -0.874 . . . . 0.72999999999999998 108.64 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.709 HD12 ' HB2' ' B' ' 9' ' ' PRO . 10.4 mt -44.87 95.71 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.135 -1.061 . . . . 0.82999999999999996 108.135 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.61 ' CB ' HG23 ' B' ' 84' ' ' ILE . 22.5 t0 -106.37 82.82 1.79 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.413 -0.804 . . . . 1.25 110.677 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.901 HG23 HD13 ' B' ' 90' ' ' LEU . 0.7 OUTLIER -64.35 -12.48 42.82 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.122 -1.066 . . . . 0.58999999999999997 108.122 178.251 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.97 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -68.07 -44.95 75.24 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.614 -1.394 . . . . 0.48999999999999999 109.614 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.575 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -68.49 163.93 22.31 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.267 -1.137 . . . . 0.5 109.648 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.506 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 2.0 m-20 -99.75 -13.9 19.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -0.856 . . . . 1.55 109.592 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.759 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -135.4 -175.66 4.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 1.3899999999999999 109.206 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.65 HG22 ' CD1' ' B' ' 33' ' ' LEU . 96.1 m -106.15 91.33 3.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.953 -1.092 . . . . 0.39000000000000001 110.229 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.977 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.48 168.03 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.694 -1.225 . . . . 0.53000000000000003 107.694 178.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.101 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -166.26 127.0 1.73 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.954 -1.092 . . . . 0.59999999999999998 110.153 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' B' ' 80' ' ' THR . 83.8 tt0 -42.39 156.73 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.511 -0.743 . . . . 2.1600000000000001 109.039 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.805 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.6 OUTLIER -47.1 143.38 3.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.14 -0.975 . . . . 2.2400000000000002 109.699 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.596 ' HE1' HG22 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -167.31 -174.91 2.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.386 -0.821 . . . . 1.6200000000000001 109.384 179.956 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.515 ' N ' ' SD ' ' B' ' 36' ' ' MET . 7.1 t -96.84 102.47 14.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 1.55 110.334 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.97 HD12 ' CG ' ' B' ' 59' ' ' TYR . 0.0 OUTLIER -97.14 172.45 4.97 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 108.231 -1.026 . . . . 1.8300000000000001 108.231 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.755 ' HD2' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -80.13 51.79 4.05 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.715 2.277 . . . . 2.1899999999999999 111.538 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.15 -160.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.318 -1.113 . . . . 1.96 110.318 179.348 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 54.65 81.54 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.441 -1.035 . . . . 5.1399999999999997 109.294 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.692 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 62.3 p-90 -159.16 -175.78 5.45 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.479 -0.763 . . . . 1.6200000000000001 109.952 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -140.89 146.56 44.41 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.724 -0.843 . . . . 2.8700000000000001 108.724 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.24 139.86 19.17 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.36 2.04 . . . . 1.73 110.556 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.797 ' HD2' HD23 ' B' ' 76' ' ' LEU . 4.5 ptpt -159.51 -173.56 4.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 2.3199999999999998 109.424 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.533 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 52.4 mtp -150.8 130.65 13.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 1.3300000000000001 109.479 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.855 ' CD1' HG21 ' A' ' 50' ' ' ILE . 10.4 pt -98.03 147.36 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.091 -1.006 . . . . 0.75 109.027 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.1 106.01 1.22 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.631 -1.788 . . . . 0.73999999999999999 108.631 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.465 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -129.18 -125.04 2.7 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.391 -1.385 . . . . 0.47999999999999998 110.892 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.866 HD12 ' C21' ' B' ' 100' ' ' DMP . 18.2 mt -84.7 120.96 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.732 -0.863 . . . . 0.51000000000000001 112.281 -177.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.459 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.91 -53.95 0.69 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.081 -1.207 . . . . 0.68999999999999995 110.081 178.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.57 -160.71 25.67 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.678 -1.369 . . . . 0.53000000000000003 109.678 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.612 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 4.5 m-85 -108.56 125.04 51.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.365 -1.079 . . . . 1.98 109.48 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.601 HD11 HD11 ' B' ' 47' ' ' ILE . 7.5 pt -99.05 161.71 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.129 -0.982 . . . . 0.79000000000000004 108.925 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.548 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.5 mttm -101.74 129.11 47.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.987 -1.071 . . . . 3.04 109.449 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' B' ' 78' ' ' GLY . 35.9 m -134.22 171.77 17.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.06 -1.025 . . . . 0.90000000000000002 109.702 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.572 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.6 mtt180 -117.02 105.48 12.35 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.426 -0.796 . . . . 2.5600000000000001 108.92 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -58.02 93.8 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.273 -0.892 . . . . 2.0800000000000001 109.801 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.97 ' CG ' HD12 ' B' ' 38' ' ' LEU . 15.5 m-85 -89.28 91.99 8.98 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.176 -1.046 . . . . 1.0800000000000001 108.176 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.573 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.5 m-20 -79.25 131.98 36.34 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.198 -0.939 . . . . 1.75 110.395 -178.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.573 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 81.82 62.38 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.53 0.681 . . . . 1.8999999999999999 109.96 179.672 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.914 HD12 HD13 ' B' ' 38' ' ' LEU . 50.8 mm -118.42 115.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 108.612 -0.885 . . . . 1.29 108.612 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.735 HD13 ' O ' ' B' ' 63' ' ' LEU . 3.4 tm? -65.21 85.29 0.06 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -0.807 . . . . 1.47 110.544 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.843 ' CG2' HD11 ' B' ' 89' ' ' LEU . 2.8 tt -93.06 115.12 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 107.917 -1.142 . . . . 0.68999999999999995 107.917 178.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 72.2 tt0 -89.74 112.01 23.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.033 -1.042 . . . . 2.2599999999999998 110.069 -178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 1.079 HG13 HG22 ' B' ' 13' ' ' ILE . 1.1 mp -110.58 126.73 67.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.35 -0.844 . . . . 0.84999999999999998 108.869 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.45 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.1 m 64.84 47.82 2.58 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.528 -0.732 . . . . 1.29 109.417 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.71 23.56 29.66 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.481 -1.448 . . . . 1.72 109.481 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -122.62 128.21 50.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.253 -1.145 . . . . 2.04 109.396 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.725 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -66.18 142.81 57.6 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 3.5699999999999998 109.35 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.667 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -159.17 102.95 1.62 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 1.01 109.595 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.783 HD13 ' C ' ' B' ' 62' ' ' ILE . 1.0 OUTLIER -79.2 152.18 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.89 -1.132 . . . . 1.03 108.498 179.458 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.774 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -177.03 -176.54 45.24 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 119.177 -1.487 . . . . 0.69999999999999996 110.673 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.5 m -91.49 105.91 18.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.531 -0.982 . . . . 0.92000000000000004 110.127 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.101 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -99.51 110.28 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.547 -0.721 . . . . 0.71999999999999997 109.815 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.797 HD23 ' HD2' ' B' ' 45' ' ' LYS . 3.9 mp -80.13 109.88 15.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.241 -0.912 . . . . 0.82999999999999996 109.342 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.805 HG12 ' HA ' ' B' ' 35' ' ' GLU . 3.6 t -91.14 114.08 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.041 -1.037 . . . . 0.81000000000000005 109.979 -179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -148.81 -166.72 13.21 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 108.93 -1.668 . . . . 0.71999999999999997 108.93 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.548 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.19 41.83 1.2 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.581 2.187 . . . . 0.81000000000000005 110.894 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.697 HG21 HG13 ' B' ' 32' ' ' VAL . 6.0 t -85.6 137.92 36.06 Favored Pre-proline 0 C--N 1.302 -1.479 0 O-C-N 121.159 -0.963 . . . . 0.67000000000000004 108.415 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.661 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.8 Cg_endo -79.94 16.55 1.46 Allowed 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.503 2.135 . . . . 0.60999999999999999 110.809 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.661 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.7 t -160.55 161.91 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 120.96 -1.087 . . . . 0.66000000000000003 110.012 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.585 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 74.0 m-20 -99.8 93.71 5.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 106.651 -1.611 . . . . 1.3400000000000001 106.651 177.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.61 HG23 ' CB ' ' B' ' 25' ' ' ASP . 5.3 mm -79.83 128.21 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.586 -0.696 . . . . 0.85999999999999999 112.28 -176.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.905 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -106.74 94.86 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 107.136 -1.431 . . . . 0.63 107.136 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.461 ' O ' ' HG ' ' B' ' 90' ' ' LEU . . . -83.51 -161.58 31.81 Favored Glycine 0 N--CA 1.492 2.425 0 O-C-N 121.185 -0.947 . . . . 0.63 111.249 -178.002 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.521 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 31.3 mmm180 -63.88 -40.17 95.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.684 -0.892 . . . . 4.1399999999999997 110.229 -179.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.92 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.7 p-10 -43.51 -30.56 0.59 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -0.938 . . . . 0.58999999999999997 109.447 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.92 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -105.85 -25.07 12.31 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.296 -0.878 . . . . 0.70999999999999996 109.879 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.901 HD13 HG23 ' B' ' 26' ' ' THR . 88.7 mt -74.07 -1.86 21.91 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.063 -1.023 . . . . 1.46 108.57 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.635 HG22 ' CG ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -100.06 -19.91 16.29 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.357 -0.979 . . . . 1.1200000000000001 108.357 179.049 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -86.97 -40.57 14.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.421 -0.799 . . . . 2.1800000000000002 109.269 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.799 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.3 pt -84.35 -0.55 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.18 -0.95 . . . . 0.78000000000000003 109.109 179.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 66.16 44.67 90.62 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.667 -0.973 . . . . 0.73999999999999999 110.667 179.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.581 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -75.32 149.8 38.63 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.041 -1.27 . . . . 0.70999999999999996 109.965 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.772 HG22 ' CG2' ' A' ' 4' ' ' THR . 11.7 p -142.48 128.78 19.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.646 -0.872 . . . . 0.77000000000000002 108.646 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.955 HD11 HD11 ' A' ' 97' ' ' LEU . 1.7 mp -90.36 95.18 10.06 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.377 -0.827 . . . . 0.59999999999999998 109.382 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.488 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 3.4 m-20 -106.51 128.94 54.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.164 -0.96 . . . . 0.82999999999999996 109.856 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.706 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.011 -0.995 . . . . 1.3300000000000001 109.282 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.866 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.577 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.632 0 N-CA-C 110.014 -0.802 . . . . 0.99 110.014 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.531 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 11.8 tt0 -84.07 137.75 33.41 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 108.009 -1.108 . . . . 1.72 108.009 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.715 HG12 ' HB3' ' A' ' 9' ' ' PRO . 54.4 t -140.28 96.66 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 120.781 -1.199 . . . . 0.98 110.109 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.772 ' CG2' HG22 ' B' ' 96' ' ' THR . 1.2 p -114.69 -71.98 0.72 Allowed 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.59 -0.893 . . . . 2.29 108.59 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.552 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 38.64 37.35 0.18 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.655 -0.653 . . . . 4.72 110.043 179.42 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.635 ' CG ' HG22 ' B' ' 91' ' ' THR . 6.6 m95 18.04 51.38 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.433 0.635 . . . . 1.62 111.277 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.544 ' N ' ' O ' ' A' ' 5' ' ' LEU . 7.5 mt-30 -157.83 -167.29 2.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.56 -0.713 . . . . 2.86 109.31 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.506 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 8.4 mtt180 -73.89 119.29 75.42 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 2.86 109.429 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.996 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.3 Cg_endo -77.92 77.2 4.01 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.281 1.987 . . . . 0.8 110.167 179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.735 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -84.09 146.77 27.73 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.317 -0.864 . . . . 0.99 109.754 -179.693 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.882 ' CG2' HG23 ' A' ' 66' ' ' ILE . 2.0 m -131.2 133.18 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.85 109.571 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.533 HG22 HD22 ' A' ' 19' ' ' LEU . 3.9 m -65.65 104.43 1.03 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.087 -1.008 . . . . 1.1 108.482 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.867 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -90.75 152.73 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.207 -0.933 . . . . 0.68 110.516 -178.935 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.595 ' HE3' HD11 ' A' ' 19' ' ' LEU . 17.3 tttt -124.13 93.73 4.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.471 -0.768 . . . . 1.58 109.046 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.884 HD13 HG11 ' A' ' 75' ' ' VAL . 18.7 mt -117.68 150.42 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.193 -0.942 . . . . 0.81 109.688 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.462 ' O ' ' HG3' ' A' ' 18' ' ' GLN . . . 41.92 54.62 4.31 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.098 -1.201 . . . . 1.21 110.098 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 45.68 46.54 13.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.552 -1.419 . . . . 1.09 109.552 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.502 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.4 mt-30 -142.51 165.95 26.0 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.398 -1.06 . . . . 2.32 108.964 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.867 HD23 ' O ' ' A' ' 13' ' ' ILE . 18.8 mt -138.81 129.49 26.19 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.126 -0.984 . . . . 1.18 109.848 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -150.45 166.56 29.76 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.495 -0.753 . . . . 2.34 109.092 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.735 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.0 mt-10 -79.96 134.61 36.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.133 -0.979 . . . . 2.5 109.168 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.736 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -115.05 127.71 55.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.57 109.946 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.97 HD21 ' O ' ' B' ' 27' ' ' GLY . 25.6 tp -81.3 102.4 10.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.254 -0.904 . . . . 0.6 108.613 179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.996 HD12 ' HB2' ' A' ' 9' ' ' PRO . 8.3 mt -43.94 95.46 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.334 -0.987 . . . . 0.88 108.334 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.588 ' HB2' HG23 ' A' ' 84' ' ' ILE . 22.6 t0 -98.32 72.06 2.09 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.466 -0.771 . . . . 1.37 110.726 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.637 HG21 HD13 ' A' ' 97' ' ' LEU . 5.4 m -61.0 -15.02 26.98 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.047 -1.033 . . . . 0.61 108.287 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 1.028 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -72.42 -42.2 49.66 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.638 -1.385 . . . . 0.52 109.638 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.561 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -70.57 160.39 32.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.199 -1.177 . . . . 0.49 109.76 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.445 ' OD2' ' CD ' ' B' ' 8' ' ' ARG . 1.7 m-20 -97.94 -10.39 24.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 1.63 109.512 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.814 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -136.94 -179.67 5.84 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -0.909 . . . . 1.36 109.354 179.894 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.768 HG23 HD12 ' A' ' 85' ' ' ILE . 92.9 m -104.78 88.68 2.97 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.986 -1.072 . . . . 0.6 110.443 -179.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.008 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.79 169.19 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 107.534 -1.284 . . . . 0.77 107.534 178.706 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.118 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -166.95 123.23 1.17 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.881 -1.137 . . . . 0.54 110.173 -179.096 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.598 ' N ' ' CG2' ' A' ' 80' ' ' THR . 11.0 pt-20 -44.27 155.67 0.09 Allowed 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.73 -0.841 . . . . 2.25 108.73 179.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.577 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.3 tt0 -44.34 141.22 1.94 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.164 -0.96 . . . . 2.03 109.612 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.583 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.3 OUTLIER -149.36 -160.22 1.14 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.388 -0.82 . . . . 1.46 109.779 -179.685 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.43 ' HB2' ' NE2' ' A' ' 18' ' ' GLN . 9.4 t -101.09 90.86 4.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.364 -0.835 . . . . 1.57 110.124 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 1.028 HD23 ' CD2' ' A' ' 59' ' ' TYR . 3.1 tp -126.21 142.7 43.46 Favored Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 108.615 -0.883 . . . . 1.67 108.615 179.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.512 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 33.4 Cg_endo -75.11 160.28 39.98 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.417 2.078 . . . . 2.44 110.39 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.517 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -58.0 -157.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.311 -1.116 . . . . 2.43 110.311 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.517 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 77.19 47.21 0.06 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.773 -0.839 . . . . 4.86 109.384 -179.323 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.635 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 35.0 p-90 -138.25 -170.43 2.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.644 -0.66 . . . . 1.55 109.892 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 20.6 mttt -133.38 138.65 31.86 Favored Pre-proline 0 N--CA 1.489 1.522 0 N-CA-C 108.58 -0.896 . . . . 3.29 108.58 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.84 138.45 16.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 122.065 1.843 . . . . 1.73 110.299 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.563 ' HD2' HD23 ' A' ' 76' ' ' LEU . 0.8 OUTLIER -156.49 -174.14 4.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.265 -0.897 . . . . 2.44 109.624 179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.501 ' CG ' ' CG ' ' A' ' 55' ' ' LYS . 6.3 mtp -150.56 131.56 14.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.321 -0.862 . . . . 1.43 109.212 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.848 ' CD1' HG21 ' B' ' 50' ' ' ILE . 8.7 pt -99.55 145.68 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.77 109.14 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.608 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -119.04 104.01 1.04 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.712 -1.755 . . . . 0.71 108.712 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.492 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -126.63 -126.16 2.91 Favored Glycine 0 N--CA 1.486 1.981 0 C-N-CA 119.456 -1.354 . . . . 0.52 110.829 -178.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.855 HG21 ' CD1' ' B' ' 47' ' ' ILE . 24.8 mt -83.7 120.2 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.764 -0.845 . . . . 0.57 112.237 -177.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.16 -54.46 0.61 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.092 -1.203 . . . . 0.65 110.092 178.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.07 -161.06 25.99 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.743 -1.343 . . . . 0.55 109.743 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.608 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -108.85 124.94 51.42 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.333 -1.098 . . . . 1.55 109.576 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.592 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 9.6 pt -99.43 161.11 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.166 -0.959 . . . . 0.79 108.976 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 39.6 mttt -100.11 132.32 45.55 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.135 -0.978 . . . . 2.81 109.423 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.706 HG12 ' HA3' ' A' ' 78' ' ' GLY . 29.1 m -138.7 173.67 11.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.963 -1.086 . . . . 1.01 109.924 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.584 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 5.8 mtt85 -117.43 109.55 16.92 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 108.871 -0.788 . . . . 2.69 108.871 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.406 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 11.9 tt0 -63.66 95.35 0.1 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.168 -0.957 . . . . 2.06 109.529 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 1.028 ' CD2' HD23 ' A' ' 38' ' ' LEU . 6.2 m-85 -91.28 93.46 9.08 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 108.857 -0.794 . . . . 1.18 108.857 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.544 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 16.3 m-20 -79.85 130.85 35.65 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 1.77 109.98 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.544 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.4 OUTLIER 84.35 60.2 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.722 0 CA-C-O 121.3 0.571 . . . . 2.19 110.152 179.543 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.756 ' C ' HD13 ' A' ' 72' ' ' ILE . 9.1 mm -116.74 114.76 46.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.478 -0.934 . . . . 1.38 108.478 179.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.852 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.7 tm? -66.23 86.08 0.1 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 1.47 110.415 -179.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.93 ' CD1' HD11 ' A' ' 66' ' ' ILE . 2.8 tt -92.8 120.8 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 N-CA-C 108.3 -1.0 . . . . 0.61 108.3 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.5 tt0 -92.29 107.05 18.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.984 . . . . 2.26 109.743 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.93 HD11 ' CD1' ' A' ' 64' ' ' ILE . 1.6 mp -110.21 124.64 67.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.339 -0.851 . . . . 1.0 108.989 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.474 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 65.22 50.37 1.8 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.487 -0.758 . . . . 1.57 109.431 -179.905 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 48.73 32.52 11.18 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.537 -1.425 . . . . 1.4 109.537 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.474 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 72.6 m-70 -129.95 128.01 41.24 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.216 -1.167 . . . . 2.35 109.55 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.586 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -63.12 139.13 58.74 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.295 -0.878 . . . . 3.78 109.035 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.676 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -158.99 100.03 1.55 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.165 -0.96 . . . . 0.85 110.212 -179.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.782 HD13 ' N ' ' A' ' 63' ' ' LEU . 1.0 OUTLIER -79.83 152.74 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.89 -1.131 . . . . 0.94 108.352 178.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.771 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -177.61 -177.55 46.52 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.029 -1.558 . . . . 0.69 110.998 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.468 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 3.8 m -91.02 106.39 18.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -1.041 . . . . 0.91 110.01 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.118 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.3 t -100.71 115.45 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.489 -0.757 . . . . 0.8 109.75 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.814 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.7 mp -82.93 110.57 18.03 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.275 -0.891 . . . . 0.75 109.445 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.613 HG23 ' HD2' ' A' ' 59' ' ' TYR . 13.7 t -90.31 115.11 29.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.109 -0.995 . . . . 0.82 109.828 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.706 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.46 -168.44 14.93 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.042 -1.623 . . . . 0.64 109.042 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -80.64 42.63 1.37 Allowed 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.615 2.21 . . . . 0.77 110.759 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.648 HG21 HG13 ' A' ' 32' ' ' VAL . 7.1 t -86.79 138.32 33.29 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.187 -0.946 . . . . 0.6 108.451 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.644 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.5 Cg_endo -79.27 16.55 1.36 Allowed 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.557 2.171 . . . . 0.61 111.229 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.644 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.1 t -160.79 156.89 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.883 -1.136 . . . . 0.58 110.014 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 74.4 m-20 -91.29 92.94 8.84 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 106.735 -1.58 . . . . 1.44 106.735 177.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.657 ' CG1' HG12 ' A' ' 32' ' ' VAL . 5.7 mm -80.02 129.25 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.414 -0.804 . . . . 0.7 112.249 -176.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.768 HD12 HG23 ' A' ' 31' ' ' THR . 1.1 mp -110.02 106.87 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.138 -1.43 . . . . 0.57 107.138 177.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.475 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -93.25 -162.19 36.35 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.999 -1.096 . . . . 0.51 110.575 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.502 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 25.6 mmm-85 -63.7 -38.42 91.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.635 -0.921 . . . . 4.13 109.917 -179.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.939 ' ND2' HD23 ' A' ' 89' ' ' LEU . 10.6 p-10 -43.59 -28.17 0.36 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 1.02 109.543 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.939 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.2 mm? -108.66 -29.72 8.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.853 . . . . 0.61 109.953 -179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.655 HD23 HD11 ' A' ' 93' ' ' ILE . 56.3 mt -67.55 -9.58 43.94 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.098 -1.001 . . . . 1.15 108.441 179.17 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.576 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 45.9 p -92.7 -20.46 20.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.297 -0.877 . . . . 1.0 108.74 179.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.2 mm-40 -86.82 -40.94 14.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -0.869 . . . . 2.03 108.971 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.706 HD12 ' CG ' ' B' ' 99' ' ' PHE . 1.3 pt -83.1 -5.62 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 N-CA-C 108.643 -0.873 . . . . 0.74 108.643 179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.66 31.32 65.3 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.815 -0.914 . . . . 0.69 110.815 178.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.559 ' N ' ' HB3' ' B' ' 99' ' ' PHE . . . -61.61 148.07 43.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.897 -1.355 . . . . 0.68 109.565 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.621 HG22 ' CG2' ' B' ' 4' ' ' THR . 7.1 p -144.33 131.59 20.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.298 -0.876 . . . . 0.83 108.785 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.955 HD11 HD11 ' B' ' 97' ' ' LEU . 4.5 mp -92.02 90.22 7.3 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.231 -0.918 . . . . 0.66 109.696 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.577 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.2 m120 -97.72 125.61 42.62 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.119 -0.988 . . . . 0.86 108.991 179.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.799 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 117.955 -1.021 . . . . 1.32 109.429 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.532 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.496 1.65 0 N-CA-C 110.296 -0.694 . . . . 0.88 110.296 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.577 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.5 tt0 -84.53 138.96 32.46 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.864 -1.162 . . . . 1.58 107.864 178.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.605 HG12 ' HB3' ' B' ' 9' ' ' PRO . 25.4 t -138.72 106.44 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 120.822 -1.174 . . . . 1.05 110.331 -178.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.621 ' CG2' HG22 ' A' ' 96' ' ' THR . 3.9 p -119.79 -73.26 0.65 Allowed 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.38 -0.971 . . . . 2.01 108.38 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 38.93 37.91 0.24 Allowed 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 4.44 110.12 179.211 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.576 ' CD2' ' HB ' ' A' ' 91' ' ' THR . 7.6 m0 17.92 50.94 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.229 0 CA-C-O 121.363 0.601 . . . . 1.61 111.557 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.7 mt-30 -157.86 -167.33 2.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.362 -0.836 . . . . 3.06 109.496 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.445 ' CD ' ' OD2' ' A' ' 29' ' ' ASP . 1.5 mtt180 -73.3 120.95 83.75 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.203 -0.936 . . . . 2.76 109.514 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.709 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.8 Cg_endo -77.85 72.77 5.98 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.366 2.044 . . . . 0.78 110.218 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.608 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -80.91 154.41 27.04 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.92 109.73 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.543 HG22 ' HB3' ' B' ' 22' ' ' ALA . 2.5 m -143.79 131.6 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.372 -0.83 . . . . 0.82 109.428 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.451 HG22 HD22 ' B' ' 19' ' ' LEU . 1.2 m -69.08 108.0 3.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.11 -0.993 . . . . 1.17 108.526 179.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 1.079 HG22 HG13 ' B' ' 66' ' ' ILE . 5.1 pt -96.06 151.95 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.104 -0.997 . . . . 0.77 110.61 -178.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.54 ' HE2' HD11 ' B' ' 19' ' ' LEU . 1.5 tttt -117.22 92.75 3.94 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.52 -0.918 . . . . 1.83 108.52 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.911 HG23 ' CG2' ' B' ' 62' ' ' ILE . 13.6 mt -109.88 121.25 62.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.128 -0.982 . . . . 0.87 110.477 -178.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 58.06 53.36 46.17 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.985 -1.246 . . . . 1.67 109.985 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.24 15.94 17.62 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.751 -1.339 . . . . 1.31 109.751 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 21.4 mm-40 -108.52 170.79 7.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.255 -1.144 . . . . 2.38 108.982 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 1.048 HD23 ' O ' ' B' ' 13' ' ' ILE . 14.5 mt -151.71 128.19 10.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.11 -0.994 . . . . 1.32 109.924 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 19.6 mttm -150.92 167.79 26.5 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.527 -0.733 . . . . 2.7 109.209 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.608 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.8 mt-10 -79.62 129.36 34.41 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.1 -1.0 . . . . 2.82 108.84 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.905 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -109.89 121.78 46.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.226 -0.921 . . . . 0.72 109.938 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 1.028 HD21 ' O ' ' A' ' 27' ' ' GLY . 25.3 tp -79.77 99.02 7.27 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.64 -0.874 . . . . 0.73 108.64 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.709 HD12 ' HB2' ' B' ' 9' ' ' PRO . 10.4 mt -44.87 95.71 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.135 -1.061 . . . . 0.83 108.135 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.61 ' CB ' HG23 ' B' ' 84' ' ' ILE . 22.5 t0 -106.37 82.82 1.79 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.413 -0.804 . . . . 1.25 110.677 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.901 HG23 HD13 ' B' ' 90' ' ' LEU . 0.7 OUTLIER -64.35 -12.48 42.82 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.122 -1.066 . . . . 0.59 108.122 178.251 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.97 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -68.07 -44.95 75.24 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.614 -1.394 . . . . 0.49 109.614 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.575 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -68.49 163.93 22.31 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.267 -1.137 . . . . 0.5 109.648 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.506 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 2.0 m-20 -99.75 -13.9 19.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -0.856 . . . . 1.55 109.592 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.759 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -135.4 -175.66 4.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 1.39 109.206 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.65 HG22 ' CD1' ' B' ' 33' ' ' LEU . 96.1 m -106.15 91.33 3.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.953 -1.092 . . . . 0.39 110.229 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.977 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.48 168.03 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.694 -1.225 . . . . 0.53 107.694 178.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.101 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -166.26 127.0 1.73 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.954 -1.092 . . . . 0.6 110.153 -179.127 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' B' ' 80' ' ' THR . 83.8 tt0 -42.39 156.73 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.511 -0.743 . . . . 2.16 109.039 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.805 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.6 OUTLIER -47.1 143.38 3.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.14 -0.975 . . . . 2.24 109.699 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.596 ' HE1' HG22 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -167.31 -174.91 2.73 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.386 -0.821 . . . . 1.62 109.384 179.956 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.515 ' N ' ' SD ' ' B' ' 36' ' ' MET . 7.1 t -96.84 102.47 14.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 1.55 110.334 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.97 HD12 ' CG ' ' B' ' 59' ' ' TYR . 0.0 OUTLIER -97.14 172.45 4.97 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 108.231 -1.026 . . . . 1.83 108.231 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.755 ' HD2' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -80.13 51.79 4.05 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.715 2.277 . . . . 2.19 111.538 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.15 -160.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.318 -1.113 . . . . 1.96 110.318 179.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 8.9 mmt180 54.65 81.54 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.441 -1.035 . . . . 5.14 109.294 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.692 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 62.3 p-90 -159.16 -175.78 5.45 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.479 -0.763 . . . . 1.62 109.952 -179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -140.89 146.56 44.41 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.724 -0.843 . . . . 2.87 108.724 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.24 139.86 19.17 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.36 2.04 . . . . 1.73 110.556 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.797 ' HD2' HD23 ' B' ' 76' ' ' LEU . 4.5 ptpt -159.51 -173.56 4.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 2.32 109.424 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.533 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 52.4 mtp -150.8 130.65 13.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 1.33 109.479 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.855 ' CD1' HG21 ' A' ' 50' ' ' ILE . 10.4 pt -98.03 147.36 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.091 -1.006 . . . . 0.75 109.027 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.1 106.01 1.22 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.631 -1.788 . . . . 0.74 108.631 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.465 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -129.18 -125.04 2.7 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.391 -1.385 . . . . 0.48 110.892 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.866 HD12 ' C21' ' B' ' 100' ' ' DMP . 18.2 mt -84.7 120.96 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.732 -0.863 . . . . 0.51 112.281 -177.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.459 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.91 -53.95 0.69 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.081 -1.207 . . . . 0.69 110.081 178.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.57 -160.71 25.67 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.678 -1.369 . . . . 0.53 109.678 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.612 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 4.5 m-85 -108.56 125.04 51.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.365 -1.079 . . . . 1.98 109.48 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.601 HD11 HD11 ' B' ' 47' ' ' ILE . 7.5 pt -99.05 161.71 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.129 -0.982 . . . . 0.79 108.925 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.548 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.5 mttm -101.74 129.11 47.84 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.987 -1.071 . . . . 3.04 109.449 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' B' ' 78' ' ' GLY . 35.9 m -134.22 171.77 17.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.06 -1.025 . . . . 0.9 109.702 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.572 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.6 mtt180 -117.02 105.48 12.35 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.426 -0.796 . . . . 2.56 108.92 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 -58.02 93.8 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.273 -0.892 . . . . 2.08 109.801 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.97 ' CG ' HD12 ' B' ' 38' ' ' LEU . 15.5 m-85 -89.28 91.99 8.98 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.176 -1.046 . . . . 1.08 108.176 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.573 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.5 m-20 -79.25 131.98 36.34 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.198 -0.939 . . . . 1.75 110.395 -178.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.573 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 81.82 62.38 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 121.53 0.681 . . . . 1.9 109.96 179.672 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.914 HD12 HD13 ' B' ' 38' ' ' LEU . 50.8 mm -118.42 115.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 N-CA-C 108.612 -0.885 . . . . 1.29 108.612 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.735 ' O ' HD13 ' B' ' 63' ' ' LEU . 3.4 tm? -65.21 85.29 0.06 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -0.807 . . . . 1.47 110.544 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.843 ' CG2' HD11 ' B' ' 89' ' ' LEU . 2.8 tt -93.06 115.12 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 107.917 -1.142 . . . . 0.69 107.917 178.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 72.2 tt0 -89.74 112.01 23.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.033 -1.042 . . . . 2.26 110.069 -178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 1.079 HG13 HG22 ' B' ' 13' ' ' ILE . 1.1 mp -110.58 126.73 67.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.35 -0.844 . . . . 0.85 108.869 179.521 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.505 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 1.1 m 64.84 47.82 2.58 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.528 -0.732 . . . . 1.29 109.417 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.71 23.56 29.66 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.481 -1.448 . . . . 1.72 109.481 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.505 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 89.2 m-70 -122.62 128.21 50.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.253 -1.145 . . . . 2.04 109.396 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.725 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -66.18 142.81 57.6 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -0.912 . . . . 3.57 109.35 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.667 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -159.17 102.95 1.62 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 1.01 109.595 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.783 HD13 ' C ' ' B' ' 62' ' ' ILE . 1.0 OUTLIER -79.2 152.18 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.89 -1.132 . . . . 1.03 108.498 179.458 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.774 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -177.03 -176.54 45.24 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 119.177 -1.487 . . . . 0.7 110.673 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.5 m -91.49 105.91 18.1 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.531 -0.982 . . . . 0.92 110.127 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.101 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -99.51 110.28 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.547 -0.721 . . . . 0.72 109.815 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.797 HD23 ' HD2' ' B' ' 45' ' ' LYS . 3.9 mp -80.13 109.88 15.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.241 -0.912 . . . . 0.83 109.342 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.805 HG12 ' HA ' ' B' ' 35' ' ' GLU . 3.6 t -91.14 114.08 27.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.041 -1.037 . . . . 0.81 109.979 -179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -148.81 -166.72 13.21 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 108.93 -1.668 . . . . 0.72 108.93 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.548 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.19 41.83 1.2 Allowed 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.581 2.187 . . . . 0.81 110.894 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.697 HG21 HG13 ' B' ' 32' ' ' VAL . 6.0 t -85.6 137.92 36.06 Favored Pre-proline 0 C--N 1.302 -1.479 0 O-C-N 121.159 -0.963 . . . . 0.67 108.415 179.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.661 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.8 Cg_endo -79.94 16.55 1.46 Allowed 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.503 2.135 . . . . 0.61 110.809 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.661 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.7 t -160.55 161.91 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 120.96 -1.087 . . . . 0.66 110.012 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.585 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 74.0 m-20 -99.8 93.71 5.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 106.651 -1.611 . . . . 1.34 106.651 177.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.61 HG23 ' CB ' ' B' ' 25' ' ' ASP . 5.3 mm -79.83 128.21 38.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.586 -0.696 . . . . 0.86 112.28 -176.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.905 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -106.74 94.86 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 107.136 -1.431 . . . . 0.63 107.136 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.461 ' O ' ' HG ' ' B' ' 90' ' ' LEU . . . -83.51 -161.58 31.81 Favored Glycine 0 N--CA 1.492 2.425 0 O-C-N 121.185 -0.947 . . . . 0.63 111.249 -178.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.521 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 31.3 mmm180 -63.88 -40.17 95.91 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.684 -0.892 . . . . 4.14 110.229 -179.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.92 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.7 p-10 -43.51 -30.56 0.59 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -0.938 . . . . 0.59 109.447 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.92 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -105.85 -25.07 12.31 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.296 -0.878 . . . . 0.71 109.879 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.901 HD13 HG23 ' B' ' 26' ' ' THR . 88.7 mt -74.07 -1.86 21.91 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.063 -1.023 . . . . 1.46 108.57 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.635 HG22 ' CG ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -100.06 -19.91 16.29 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.357 -0.979 . . . . 1.12 108.357 179.049 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -86.97 -40.57 14.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.421 -0.799 . . . . 2.18 109.269 179.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.799 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.3 pt -84.35 -0.55 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.18 -0.95 . . . . 0.78 109.109 179.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 66.16 44.67 90.62 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.667 -0.973 . . . . 0.74 110.667 179.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.581 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -75.32 149.8 38.63 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.041 -1.27 . . . . 0.71 109.965 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.772 HG22 ' CG2' ' A' ' 4' ' ' THR . 11.7 p -142.48 128.78 19.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.646 -0.872 . . . . 0.77 108.646 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.955 HD11 HD11 ' A' ' 97' ' ' LEU . 1.7 mp -90.36 95.18 10.06 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.377 -0.827 . . . . 0.6 109.382 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.531 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 1.4 m120 -106.51 128.94 54.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.164 -0.96 . . . . 0.83 109.856 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.706 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.011 -0.995 . . . . 1.33 109.282 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.866 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_